Retrieve available abstracts of 22 articles: HTML format
Single Articles
June 2025
KOREN MJ, Vega RB, Agrawal N, Xu Y, et al An Oral PCSK9 Inhibitor for Treatment of Hypercholesterolemia: The PURSUIT
Randomized Trial.
J Am Coll Cardiol. 2025;85:1996-2007. PubMedAbstract available
May 2025
NORDESTGAARD AT, Tybjaerg-Hansen A, Mansbach H, Kersten S, et al Target Populations for Novel Triglyceride-Lowering Therapies.
J Am Coll Cardiol. 2025;85:1876-1897. PubMedAbstract available
XIE X, Shi X, Zhang Y, Su S, et al Angiopoietin-Like 3 Antibody Therapy in Patients With Suboptimally
Controlled Hyperlipidemia: A Phase 2 Study.
J Am Coll Cardiol. 2025;85:1821-1835. PubMedAbstract available
RAY KK, Linnebjerg H, Michael LF, Shen X, et al Effect of ANGPTL3 Inhibition With Solbinsiran in Preclinical and
Early Human Studies.
J Am Coll Cardiol. 2025;85:1803-1818. PubMedAbstract available
BALLANTYNE CM, Gaudet D, Rosenson RS, Hegele RA, et al Effect of Targeting ApoC-III With Plozasiran on Lipoprotein Particle Size
and Number in Hypertriglyceridemia.
J Am Coll Cardiol. 2025;85:1839-1854. PubMedAbstract available
November 2024
SUN Y, Lv Q, Guo Y, Wang Z, et al Recaticimab as Add-On Therapy to Statins for Nonfamilial Hypercholesterolemia:
The Randomized, Phase 3 REMAIN-2 Trial.
J Am Coll Cardiol. 2024;84:2037-2047. PubMedAbstract available
XU M, Wang Z, Zhang Y, Liu Y, et al Recaticimab Monotherapy for Nonfamilial Hypercholesterolemia and Mixed
Hyperlipemia: The Phase 3 REMAIN-1 Randomized Trial.
J Am Coll Cardiol. 2024;84:2026-2036. PubMedAbstract available
September 2024
TOTH PP Triglycerides and Cardiovascular Risk: Getting to the Heart of the Matter.
J Am Coll Cardiol. 2024;84:1007-1009. PubMed
April 2024
WRIGHT RS, Leiter LA, Lesogor A, Ray KK, et al Reply: Evaluation of the Inclisiran Safety in High-Risk Populations.
J Am Coll Cardiol. 2024;83:e129. PubMed
JIANG X, Zhang Z, Ding H Evaluation of the Inclisiran Safety in High-Risk Populations.
J Am Coll Cardiol. 2024;83:e127. PubMed
March 2024
SZAREK M, Bhatt DL, Miller M, Brinton EA, et al Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent
Ethyl.
J Am Coll Cardiol. 2024 Mar 15:S0735-1097(24)00384. PubMedAbstract available
BLAHA MJ, Bhatia HS Lipoprotein(a), Residual Cardiovascular Risk, and the Search for Targeted
Therapy.
J Am Coll Cardiol. 2024 Mar 9:S0735-1097(24)00944. PubMed
December 2023
BALLANTYNE CM, Minhas AMK, Orringer CE Inclisiran: Where Are We on Safety, Efficacy, and Clinical Effectiveness of siRNA
Therapies for Prevention?
J Am Coll Cardiol. 2023;82:2262-2264. PubMed
WRIGHT RS, Koenig W, Landmesser U, Leiter LA, et al Safety and Tolerability of Inclisiran for Treatment of Hypercholesterolemia in 7
Clinical Trials.
J Am Coll Cardiol. 2023;82:2251-2261. PubMedAbstract available
October 2023
GIDDING SS Childhood Screening for Familial Hypercholesterolemia: JACC Review Topic of the
Week.
J Am Coll Cardiol. 2023;82:1558-1563. PubMedAbstract available
August 2023
BEN-YEHUDA O Combination Therapy With Lower Statin Dose and the Race to LDL-C Goal: A Clear
Winner?
J Am Coll Cardiol. 2023;82:411-413. PubMed
LEE SJ, Joo JH, Park S, Kim C, et al Combination Lipid-Lowering Therapy in Patients Undergoing Percutaneous
Coronary Intervention.
J Am Coll Cardiol. 2023;82:401-410. PubMedAbstract available
July 2023
KALRA DK, Vorla M, Michos ED, Agarwala A, et al Dyslipidemia in Human Immunodeficiency Virus Disease: JACC Review Topic of the
Week.
J Am Coll Cardiol. 2023;82:171-181. PubMedAbstract available
MORALES J, Handelsman Y Cardiovascular Outcomes in Patients With Diabetes and Kidney Disease: JACC Review
Topic of the Week.
J Am Coll Cardiol. 2023;82:161-170. PubMedAbstract available
May 2023
KAZI DS, DeJong C, Chen R, Wadhera RK, et al The Inflation Reduction Act and Out-of-Pocket Drug Costs for
Medicare Beneficiaries With Cardiovascular Disease.
J Am Coll Cardiol. 2023;81:2103-2111. PubMedAbstract available
April 2023
CHOI D, Malick WA, Koenig W, Rader DJ, et al Familial Hypercholesterolemia: Challenges for a High-Risk Population: JACC Focus
Seminar 1/3.
J Am Coll Cardiol. 2023;81:1621-1632. PubMedAbstract available
BALLANTYNE CM, Banka P, Mendez G, Garcia R, et al Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
J Am Coll Cardiol. 2023;81:1553-1564. PubMedAbstract available